Immunome annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Immunome R&D Spending Growth & History (IMNM)
Immunome's r&d spending was $177.3M for fiscal 2025.
View full Immunome company overviewImmunome annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $177.3M | $47.7M | +36.86% |
| 2024 | 2024-12-31 | $129.5M | $106.5M | +461.06% |
| 2023 | 2023-12-31 | $23.1M | −$183,000 | −0.79% |
| 2022 | 2022-12-31 | $23.3M | $9.2M | +64.93% |
| 2021 | 2021-12-31 | $14.1M | $6.6M | +88.49% |
| 2020 | 2020-12-31 | $7.5M | −$1.3M | −15.15% |
| 2019 | 2019-12-31 | $8.8M | — | — |
Immunome quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $59.9M | $19.4M | +48.04% |
| Q1 2026 | 2026-03-31 | $46.4M | $9.5M | +25.79% |
| Q4 2025 | 2025-12-31 | $50.8M | $2.9M | +6.01% |
| Q3 2025 | 2025-09-30 | $49.2M | $12.0M | +32.24% |
| Q2 2025 | 2025-06-30 | $40.5M | $11.4M | +39.09% |
| Q1 2025 | 2025-03-31 | $36.9M | $21.5M | +139.91% |
| Q4 2024 | 2024-12-31 | $47.9M | $38.3M | +396.94% |
| Q3 2024 | 2024-09-30 | $37.2M | $33.4M | +873.06% |
| Q2 2024 | 2024-06-30 | $29.1M | $23.4M | +408.80% |
| Q1 2024 | 2024-03-31 | $15.4M | $11.5M | +292.77% |
| Q4 2023 | 2023-12-31 | $9.6M | $5.4M | +126.65% |
| Q3 2023 | 2023-09-30 | $3.8M | −$1.4M | −26.83% |
| Q2 2023 | 2023-06-30 | $5.7M | −$1,000 | −0.02% |
| Q1 2023 | 2023-03-31 | $3.9M | −$4.2M | −51.56% |
| Q4 2022 | 2022-12-31 | $4.3M | −$133,000 | −3.03% |
| Q3 2022 | 2022-09-30 | $5.2M | $712,000 | +15.78% |
| Q2 2022 | 2022-06-30 | $5.7M | $2.5M | +76.83% |
| Q1 2022 | 2022-03-31 | $8.1M | $6.1M | +308.19% |
| Q4 2021 | 2021-12-31 | $4.4M | $2.5M | +138.96% |
| Q3 2021 | 2021-09-30 | $4.5M | $2.9M | +174.51% |
| Q2 2021 | 2021-06-30 | $3.2M | $1.3M | +70.88% |
| Q1 2021 | 2021-03-31 | $2.0M | −$136,000 | −6.43% |
| Q4 2020 | 2020-12-31 | $1.8M | — | — |
| Q3 2020 | 2020-09-30 | $1.6M | −$590,000 | −26.41% |
| Q2 2020 | 2020-06-30 | $1.9M | — | — |
| Q1 2020 | 2020-03-31 | $2.1M | — | — |
| Q3 2019 | 2019-09-30 | $2.2M | — | — |
Immunome r&d spending trends
Over the last five fiscal years, Immunome's r&d spending increased from $7.5M to $177.3M, a change of $169.8M. The latest reported quarter, Q2 2026, shows $59.9M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunome source filings ↗